Table 1 Summary of treatment effects on EEG measures in APP23 and non-transgenic controls
Riluzole | MK801 | SB203580 | ||||
|---|---|---|---|---|---|---|
non-tg | APP23 | non-tg | APP23 | non-tg | APP23 | |
Hypersynchronicity | ND | ↑↑ | ND | ↑ | ND | ↑ |
Spike trains per 2 hours (n/120 min) | 11.6 ± 3.2 | 6.0 ± 1.2 | 8.3 ± 2.7 | |||
Spikes/spike train | 69.4 ± 3.9 | 40.9 ± 7.0 | 12.4 ± 1.1 | |||
Spike train duration (s) | 12.38 ± 2.09 | 6.97 ± 0.74 | 4.24 ± 0.35 | |||
Theta power | ↓ | ↑ | ↑ | ↑ | → | → |
Theta frequency | ↓ | ↓ | → | → | ↓ | → |
Gamma power | ↓ | ↑ | ↓ | ↓ | ↓ | ↓ |
Cross-frequency coupling | → | ↑ | → | → | → | → |
p38 MAPK activity | nt | → | nt | ↓ | ↓ | ↓ |